published_or_final_version / Microbiology / Master / Master of Philosophy

No description available.

The purpose of this study was to focus on the efficacy of a dynamic breath exerciser called the Breath Builder™ and its effects on clarinet players’ performance abilities and/or lung functions. The study sample consisted of 15 clarinetists, a combination of undergraduate and graduates from the clarinet studio at the University of Arizona, ages 18 - 27. The eight-week study consisted of two phases. During Phase 1, subjects in experimental group 1 used the Breath Builder™ three times a day, five times a week. The control group was not given Breath Builders™ and continued with their normal practice routine. In Phase 2, the control group was given Breath Builders™ and relabeled as experimental group 2. Experimental group 1 stopped using the Breath Builder™ and was relabeled as experimental group 3. Following this cessation, the subjects in experimental group 3 were measured to note any change in lung function or performance. Some of the pulmonary lung function measurements used for this study were, Forced Vital Capacity (FVC), Maximal Inspiratory Pressure (MIP), Maximal Inspiratory Pressure in 1 second (MIP1), and Maximal Expiratory Pressure (MEP). Musical abilities measured were tone, note duration and phrase duration. A significant interaction effect was found regarding MIP and MIP₁.

Background: Chronic obstructive pulmonary disease (COPD) is a devastating illness that affects 4.3% of the population of British Columbia over the age of 45 years. Asthma is known to coexist in 10-20% of individuals with obstructive lung disease, and adds to the substantial burden of illness posed by COPD alone. Inhaled corticosteroids (ICS) are currently recommended for the management of COPD among individuals with frequent exacerbations; however, the ability of inhaled corticosteroids to reduce death and hospitalizations among individuals with COPD is controversial. Less is known about the effectiveness of ICS among individuals who are afflicted with both COPD and asthma. Methods: We used a retrospective cohort study design and administrative data to estimate the relative effectiveness of ICS in reducing hospitalizations or death among individuals with concomitant asthma and COPD, compared with individuals with COPD alone. We used an extended Cox model to estimate this association, with a time-varying measure of exposure to ICS. Results: We did not find any association between ICS and hazard of death or hospitalization among individuals with COPD alone (HR = 0.99; 95% CI: 0.94 – 1.05), however the hazard was 18% lower (HR = 0.82; 95% CI: 0.69-0.99) among individuals with concomitant disease. Conclusions: Individuals with combined COPD and asthma show significant benefit from the use of ICS and are more responsive to the effects of ICS than individuals with COPD alone.

No description available.

No description available.

No description available.

No description available.

Bleomycin-induced pulmonary fibrosis (BIPF) is a disease caused by the chemotherapeutic bleomycin in which normal lung tissue is replaced with fibrous tissue that is unable to fulfill the normal functions of oxygen exchange in the lung. The development of this disease is dictated, in part, by a set of genes governing susceptibility. Knowledge of such genetic modifiers offers novel therapeutic targets and improved understanding of the pathways involved in the disease process. Our method integrates different data types to identify genes that have a single nucleotide polymorphism (SNP) disrupting a transcription factor binding site that modifies the outcome of BIPF. Our current approach examines over 7 million SNPs, phenotypes from 11 inbred mice strains, mRNA expression data, linkage data, and over 600 transcription factor binding sites from the TRANSFAC database. Each gene is scored with respect to each data type and then integrated using a weighted multiplicative model. Our integrative method produces a list of potential genetic modifiers that will be validated using allelic imbalance tests, existing knockout mice if available, siRNA or antibodies. By investigating these genes, we have identified several that are related to known genetic modifiers or others that make biological sense such as H2-Q2, an antigen presentation gene, and Runx1, a transcription factor known to interact with the known BIPF genetic modifiers Smad3 and Cdkn1a.

Pulmonary arterial hypertension (PAH) is a lethal disease characterized by excessive proliferation of pulmonary vascular cells, such as endothelial cells (ECs). Hereditary (H) PAH is mainly caused by ―loss-of-function‖ mutations in the gene coding for the bone morphogenetic protein type II receptor (BMPR2). However, the mechanisms by which these mutations cause PAH remain unclear. The hypothesis of this thesis was that BMPR2 mutations produce an imbalance in EC protein expression and/or activity that is integrally related to the development of abnormalities in lung vascular function and structure in HPAH. Patient-specific blood-outgrowth endothelial cells (BOECs) expanded ex vivo from peripheral blood mononuclear cells from patients with HPAH and healthy subjects were used to examine the consequences of BMPR2 mutations on the BOEC protein expression profile as well as on their functionality. Functional analyses of the BOECs revealed that HPAH-derived BOECs are more susceptible to apoptosis and more proliferative compared with healthy controls. Protein isolates of BOECs from patients with HPAH and from healthy subjects were subjected to 2-D gel electrophoresis and stained for total proteins and phosphoproteins, and to a quantitative computerassisted analysis. Differentially regulated proteins were identified by mass spectrometry (LC-MS/MS). Of the 416 total proteins detected under basal conditions, 11 were significantly downregulated in HPAH-derived BOECs and 11, including the translationally controlled tumor protein (TCTP), were upregulated. TCTP has previously been shown to be involved in systemic arteriolar remodeling, inflammation and growth. Therefore, the potential role of TCTP in PAH was studied in vivo in the SU5416 rat model of severe angioproliferative PAH. Immunofluorescence staining revealed high expression of TCTP in arteriolar ECs of PAH lungs tightly localized to proliferating cells within occlusive intimal lesions; whereas, only minimal TCTP expression was seen in vascular ECs of normal lungs. Similarly, abundant TCTP immunostaining was also seen in human PAH lung sections, again associated with complex vascular lesions. In BOECs, TCTP was found to participate in cell growth and survival. These data suggest that TCTP could play an important role in PAH by mediating pro-survival and growth signaling in vascular cells, contributing to occlusive pulmonary vascular remodeling triggered by EC apoptosis.